Plain-English translation of NCT07310784 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new treatment called LM103 TILs for advanced melanoma — a type of skin cancer that has spread and has not responded to previous standard treatments. LM103 TILs works by taking immune cells that are already fighting your tumor, growing many more of them in a laboratory, and then putting them back into your body to continue the fight. The trial will compare this new treatment to standard chemotherapy to see which works better.
Many patients with advanced melanoma stop responding to current treatments like immunotherapy drugs or targeted therapies, leaving them with few options. This medication represents a different approach that uses your own immune system's cells, and researchers believe it could help patients who have run out of other effective treatments.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will first have a small surgical procedure or biopsy to remove a sample of your tumor tissue — this is sent to a laboratory where your immune cells are isolated and grown for several weeks. Once ready, you will receive your treatment: either the new cell infusion (LM103 TILs) or standard chemotherapy, depending on which group you are randomly assigned to. You will then have regular follow-up visits over 24 months to check how well the treatment is working, monitor for side effects, and have imaging scans to measure your tumors.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China